Clinical Trials on Major Depressive Disorder, Recurrent in Ireland

Total 367 results

GlaxoSmithKline

Completed

Depression Study In Elderly Patients

Depressive Disorder, Major | Major Depressive Disorder (MDD)

United States
Novartis

Completed

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Major Depressive Disorder (MDD)

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Pfizer

Completed

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile
Avanir Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Depressive Disorder, Treatment-Resistant

United States
Alto Neuroscience

Recruiting

Study of ALTO-300 in MDD

Major Depressive Disorder

United States
Axsome Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)

Treatment Resistant Major Depressive Disorder

United States
Vanda Pharmaceuticals

Completed

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder (MAGELLAN)

Major Depressive Disorder

United States
Sirtsei Pharmaceuticals, Inc.

Completed

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
AstraZeneca

Completed

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder (DIAMOND)

Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Major Depressive Disorder

United States
Euthymics BioScience, Inc.

Completed

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico
Eli Lilly and Company

Completed

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Major Depressive Disorder

United Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
Alkermes, Inc.

Completed

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

Major Depressive Disorder

United States, Australia, Canada
AstraZeneca

Completed

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder (MOONSTONE)

Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Major Depressive Disorder

United States
Bristol-Myers Squibb

Completed

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Major Depressive Disorder

United States, Puerto Rico
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (VLZ-MD-21)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (STEP-D222)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) (VLZ-MD-22)

Major Depressive Disorder

United States, Canada
Eli Lilly and Company

Completed

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Major Depressive Disorder

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Recruiting

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Depression | Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

United States
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, India, Puerto Rico
Takeda

Completed

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Russian Federation, South Africa, France, Ukraine, Slovakia
Alkermes, Inc.

Completed

A Long-Term Safety Study of ALKS 5461

Major Depressive Disorder

United States, Canada, Germany, Puerto Rico, Bulgaria, Australia, Poland, Hungary
Forest Laboratories

Completed

Safety Study of F2695 SR in Major Depressive Disorder (LVM-MD-04)

Major Depressive Disorder

United States
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
Relmada Therapeutics, Inc.

Completed

Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study in Prevention of Re-emergence of Depression Symptoms

Major Depressive Disorder

United States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Storytelling Video Intervention for Depressed Primary Care Patients - Pilot Trial (sTVi-RCT)

Major Depressive Disorder

United States
Praxis Precision Medicines

Completed

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

Major Depressive Disorder

United States, Australia
Eli Lilly and Company

Completed

A Study in Depression and Associated Painful Physical Symptoms

Major Depressive Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Anxiety | Major Depressive Disorder

United States
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial (sTVi-Open)

Major Depressive Disorder

United States
Forest Laboratories
Gedeon Richter Ltd.

Completed

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Puerto Rico
Cervel Neurotech, Inc.

Completed

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

Depressive Disorder, Major

United States
Forest Laboratories

Completed

Escitalopram in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories
Gedeon Richter Ltd.

Completed

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Puerto Rico
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder | MDD

United States, Puerto Rico
Axsome Therapeutics, Inc.

Completed

A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI)

Depression | Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

Major Depressive Disorder

United States, Canada
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Depression | Major Depressive Disorder

United States, India

3

Subscribe